In addition, and has also been reported, both ABT‐263 and ABT‐199 cause neutropenia in the clinic via BCL‐2 inhibition; this neutropenia can be exacerbated by concomitant treatment with chemotherapy [71]. Here, BCL2 is linked to neutropenia.